BioXcel Therapeutics, Inc. Financing Cash Flow
BioXcel Therapeutics, Inc. (BTAI) reported Financing Cash Flow of $2.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- BioXcel Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $2.72M, a 1884.67% increase year-over-year.
- BioXcel Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $232.00K, a 98.24% decline year-over-year.
- BioXcel Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $5.65M, a 32.06% increase year-over-year.
- BioXcel Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $37.53M, a 8166.96% increase year-over-year.
- BioXcel Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $56.52M, a 54.17% increase from fiscal 2024.
- BioXcel Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $36.66M, a 38.22% increase from fiscal 2023.
- BioXcel Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $26.52M, a 72.44% decline from fiscal 2022.
- BioXcel Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $96.24M, a 6.06% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.95M 10-Q · filed 2026-08-13 | $8.60M derived: sum of 3 quarters · filed 2026-08-13 | $46.13M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $232.00K 10-Q · filed 2026-05-15 | $5.88M derived: sum of 2 quarters · filed 2026-05-15 | $43.41M derived: sum of 3 quarters · filed 2026-05-15 | $43.55M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | $5.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $43.18M derived: sum of 2 quarters · filed 2026-03-27 | $43.32M derived: sum of 3 quarters · filed 2026-08-13 | $56.52M 10-K · filed 2026-03-27 | ||
| 2025-09-30 | $37.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $37.67M derived: sum of 2 quarters · filed 2026-08-13 | $50.87M 10-Q · filed 2025-11-12 | $55.15M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $137.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $13.34M 10-Q · filed 2026-08-13 | $17.61M derived: sum of 3 quarters · filed 2026-08-13 | $18.07M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $13.20M 10-Q · filed 2026-05-15 | $17.48M derived: sum of 2 quarters · filed 2026-05-15 | $17.93M derived: sum of 3 quarters · filed 2026-05-15 | $23.24M derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $4.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $4.73M derived: sum of 2 quarters · filed 2026-03-27 | $10.03M derived: sum of 3 quarters · filed 2026-03-27 | $36.66M 10-K · filed 2026-03-27 | ||
| 2024-09-30 | $454.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $5.76M derived: sum of 2 quarters · filed 2025-11-12 | $32.38M 10-Q · filed 2025-11-12 | $34.51M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $5.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $31.93M 10-Q · filed 2025-08-12 | $34.05M derived: sum of 3 quarters · filed 2025-08-12 | $34.05M derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2024-03-31 | $26.63M 10-Q · filed 2025-05-12 | $28.75M derived: sum of 2 quarters · filed 2025-05-12 | $28.75M derived: sum of 3 quarters · filed 2025-05-12 | $29.00M derived: sum of 4 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $2.12M derived: sum of 2 quarters · filed 2025-03-28 | $2.37M derived: sum of 3 quarters · filed 2025-03-28 | $26.52M 10-K · filed 2025-03-28 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $250.00K derived: sum of 2 quarters · filed 2024-11-14 | $24.40M 10-Q · filed 2024-11-14 | $24.45M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $250.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $24.40M 10-Q · filed 2024-08-06 | $24.45M derived: sum of 3 quarters · filed 2024-08-06 | $54.50M derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $24.15M 10-Q · filed 2024-05-09 | $24.20M derived: sum of 2 quarters · filed 2024-05-09 | $54.25M derived: sum of 3 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $30.10M derived: sum of 2 quarters · filed 2024-03-22 | $96.24M 10-K · filed 2024-03-22 | |||
| 2022-09-30 | $30.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $96.19M 10-Q · filed 2023-11-14 | ||||
| 2022-06-30 | $66.14M 10-Q · filed 2023-08-14 | |||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $71.00K derived: sum of 2 quarters · filed 2023-03-16 | $101.59M derived: sum of 3 quarters · filed 2023-03-16 | $102.45M 10-K · filed 2023-03-16 | ||
| 2021-09-30 | $71.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $101.59M derived: sum of 2 quarters · filed 2022-11-14 | $102.45M 10-Q · filed 2022-11-14 | $102.68M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $101.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $102.38M 10-Q · filed 2022-08-11 | $102.61M derived: sum of 3 quarters · filed 2022-08-11 | $289.64M derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $852.00K 10-Q · filed 2022-05-09 | $1.08M derived: sum of 2 quarters · filed 2022-05-09 | $188.11M derived: sum of 3 quarters · filed 2022-05-09 | $188.38M derived: sum of 4 quarters · filed 2022-05-09 | ||
| 2020-12-31 | $233.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $187.26M derived: sum of 2 quarters · filed 2022-03-11 | $187.53M derived: sum of 3 quarters · filed 2022-03-11 | $247.36M 10-K · filed 2022-03-11 | ||
| 2020-09-30 | $187.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $187.30M derived: sum of 2 quarters · filed 2021-11-10 | $247.13M 10-Q · filed 2021-11-10 | $247.22M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $271.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $60.10M 10-Q · filed 2021-08-10 | $60.19M derived: sum of 3 quarters · filed 2021-08-10 | $78.01M derived: sum of 4 quarters · filed 2021-08-10 | ||
| 2020-03-31 | $59.83M 10-Q · filed 2021-05-10 | $59.92M derived: sum of 2 quarters · filed 2021-05-10 | $77.74M derived: sum of 3 quarters · filed 2021-05-10 | $77.66M derived: sum of 4 quarters · filed 2021-05-10 | ||
| 2019-12-31 | $95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $17.91M derived: sum of 2 quarters · filed 2021-03-12 | $17.83M derived: sum of 3 quarters · filed 2021-03-12 | $17.83M 10-K · filed 2021-03-12 | $18.01M 10-K · filed 2020-03-09 | |
| 2019-09-30 | $17.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $17.74M derived: sum of 2 quarters · filed 2020-11-12 | $17.74M 10-Q · filed 2020-11-12 | $17.91M 10-Q · filed 2019-11-14 | $17.68M derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | -$79.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$78.00K 10-Q · filed 2020-08-14 | -$136.00K derived: sum of 3 quarters · filed 2020-08-14 | -$115.00K derived: sum of 4 quarters · filed 2020-08-14 | ||
| 2019-03-31 | $1.00K 10-Q · filed 2020-05-12 | -$57.00K derived: sum of 2 quarters · filed 2020-05-12 | -$36.00K derived: sum of 3 quarters · filed 2020-05-12 | -$62.00K derived: sum of 4 quarters · filed 2020-05-12 | ||
| 2018-12-31 | -$58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | -$37.00K derived: sum of 2 quarters · filed 2020-03-09 | -$63.00K derived: sum of 3 quarters · filed 2020-03-09 | $55.53M 10-K · filed 2020-03-09 | ||
| 2018-09-30 | $21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$5.00K derived: sum of 2 quarters · filed 2019-11-14 | $55.59M 10-Q · filed 2019-11-14 | $56.82M derived: sum of 4 quarters · filed 2019-11-14 | ||
| 2018-06-30 | -$26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $55.56M 10-Q · filed 2019-08-06 | $56.80M derived: sum of 3 quarters · filed 2019-08-06 | $57.59M derived: sum of 4 quarters · filed 2019-08-06 | ||
| 2018-03-31 | $55.59M 10-Q · filed 2019-05-07 | $56.82M derived: sum of 2 quarters · filed 2019-05-07 | $57.61M derived: sum of 3 quarters · filed 2019-05-07 | $58.24M derived: sum of 4 quarters · filed 2019-05-07 | ||
| 2017-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $2.02M derived: sum of 2 quarters · filed 2019-03-12 | $2.65M derived: sum of 3 quarters · filed 2019-03-12 | $3.08M 10-K · filed 2019-03-12 | ||
| 2017-09-30 | $791.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $1.42M derived: sum of 2 quarters · filed 2018-11-09 | $1.85M 10-Q · filed 2018-11-09 | |||
| 2017-06-30 | $630.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $1.06M 10-Q · filed 2018-08-08 | ||||
| 2017-03-31 | $431.00K 10-Q · filed 2018-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |